Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_001321571.2(CAMK2D):c.567T>A(p.Asp189Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
CAMK2D (HGNC:1462): (calcium/calmodulin dependent protein kinase II delta) The product of this gene belongs to the serine/threonine protein kinase family and to the Ca(2+)/calmodulin-dependent protein kinase subfamily. Calcium signaling is crucial for several aspects of plasticity at glutamatergic synapses. In mammalian cells, the enzyme is composed of four different chains: alpha, beta, gamma, and delta. The product of this gene is a delta chain. Alternative splicing results in multiple transcript variants encoding distinct isoforms. Distinct isoforms of this chain have different expression patterns.[provided by RefSeq, Nov 2008]
Uncertain significance, criteria provided, single submitter
clinical testing
GeneDx
Jul 15, 2024
Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge -
Gain of glycosylation at Y191 (P = 0.0099);Gain of glycosylation at Y191 (P = 0.0099);Gain of glycosylation at Y191 (P = 0.0099);Gain of glycosylation at Y191 (P = 0.0099);Gain of glycosylation at Y191 (P = 0.0099);Gain of glycosylation at Y191 (P = 0.0099);Gain of glycosylation at Y191 (P = 0.0099);Gain of glycosylation at Y191 (P = 0.0099);Gain of glycosylation at Y191 (P = 0.0099);Gain of glycosylation at Y191 (P = 0.0099);